| 产品名称： | CEM/C1 |
|---|---|
| 商品货号： | TS212397 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | T lymphoblast |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute lymphoblastic leukemia |
| Age： | 4 years |
| Gender： | Female |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Images： |  |
| Derivation： | CEM/C1 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119). The cell line was selected and subcloned in 1991 for resistance to CPT.
|
| Clinical Data： | 4 years Caucasian female |
| Comments： | This cell line exhibits cross resistance to both the water soluble (topotecan) and water insoluble (9-amino-CPT and 10,11-methylenedioxy-CPT) analogs of CPT. CEM/C1 cells are approximately 31 fold less sensitive to CPT than the parental CEM cells. CEM/C1 cells display atypical multidrug resistance (MDR) and altered topoisomerase I catalytic activity.
Resistance to CPT is stable for up to six months. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition or replacement of medium. When replacing media, centrifuge cells and resuspend cell pellet in fresh medium at 1- 2 x 105 viable cells/mL. Maintain cultures at cell concentrations between 1 x 105 and 2 x 106 viable cells/mL. Medium Renewal: 2 to 3 times a week. |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37°C |
| Population Doubling Time： | 26 hrs |
| Name of Depositor： | WG Harker |
| Deposited As： | Homo sapiens |
| Year of Origin： | 1991 |
| References： | Kapoor R, et al. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7: 83-95, 1995. PubMed: 7579731 Fujimori A, et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55: 1339-1346, 1995. PubMed: 7882333 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | CEM/C1 |
|---|---|
| 商品货号： | TS212397 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | T lymphoblast |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute lymphoblastic leukemia |
| Age： | 4 years |
| Gender： | Female |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Images： | |
| Derivation： | CEM/C1 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119). The cell line was selected and subcloned in 1991 for resistance to CPT.
|
| Clinical Data： | 4 years Caucasian female |
| Comments： | This cell line exhibits cross resistance to both the water soluble (topotecan) and water insoluble (9-amino-CPT and 10,11-methylenedioxy-CPT) analogs of CPT. CEM/C1 cells are approximately 31 fold less sensitive to CPT than the parental CEM cells. CEM/C1 cells display atypical multidrug resistance (MDR) and altered topoisomerase I catalytic activity.
Resistance to CPT is stable for up to six months. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition or replacement of medium. When replacing media, centrifuge cells and resuspend cell pellet in fresh medium at 1- 2 x 105 viable cells/mL. Maintain cultures at cell concentrations between 1 x 105 and 2 x 106 viable cells/mL. Medium Renewal: 2 to 3 times a week. |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37°C |
| Population Doubling Time： | 26 hrs |
| Name of Depositor： | WG Harker |
| Deposited As： | Homo sapiens |
| Year of Origin： | 1991 |
| References： | Kapoor R, et al. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7: 83-95, 1995. PubMed: 7579731 Fujimori A, et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55: 1339-1346, 1995. PubMed: 7882333 |
